Literature DB >> 3931405

Mannoside storage and axonal dystrophy in sensory neurones of swainsonine-treated rats: morphogenesis of lesions.

C R Huxtable, P R Dorling.   

Abstract

Young rats were treated with swainsonine for up to 200 days at a dose rate that restricted neuronal mannoside storage to neurones not protected by the blood/brain barrier. In lumbar dorsal root ganglion neurones, mannoside storage in the cell body developed in parallel to dystrophic changes at the extremities of peripherally and centrally directed axons. The dystrophic process involved the accumulation of autophagic structures. In the CNS, axonal dystrophy was confined to areas receiving long processes from affected neurones. The results suggest that axonal dystrophy is a direct consequence of the lysosomal storage process in parent cell bodies. The possible relationship of axonal dystrophy to neuronal lysosomal function is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3931405     DOI: 10.1007/bf00688958

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  28 in total

Review 1.  Drug-induced experimental lipidosis in the nervous system.

Authors:  D Drenckhahn; R Lüllmann-Rauch
Journal:  Neuroscience       Date:  1979       Impact factor: 3.590

2.  Neuronal transport of acid hydrolases and peroxidase within the lysosomal system or organelles: involvement of agranular reticulum-like cisterns.

Authors:  R D Broadwell; C Oliver; M W Brightman
Journal:  J Comp Neurol       Date:  1980-04-01       Impact factor: 3.215

3.  Swainsonine inhibits the biosynthesis of complex glycoproteins by inhibition of Golgi mannosidase II.

Authors:  D R Tulsiani; T M Harris; O Touster
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

Review 4.  The origin and fate of secretory packages, especially synaptic vesicles.

Authors:  E Holtzman
Journal:  Neuroscience       Date:  1977       Impact factor: 3.590

5.  Abnormal glycosylation of human cellular fibronectin in the presence of swainsonine.

Authors:  R G Arumugham; M L Tanzer
Journal:  J Biol Chem       Date:  1983-10-10       Impact factor: 5.157

6.  Swainsonine prevents the processing of the oligosaccharide chains of influenza virus hemagglutinin.

Authors:  A D Elbein; P R Dorling; K Vosbeck; M Horisberger
Journal:  J Biol Chem       Date:  1982-02-25       Impact factor: 5.157

7.  Caprine beta-mannosidosis: clinical and pathological features.

Authors:  M Z Jones; J G Cunningham; A W Dade; D M Alessi; U V Mostosky; J R Vorro; J T Benitez; K L Lovell
Journal:  J Neuropathol Exp Neurol       Date:  1983-05       Impact factor: 3.685

8.  Animal model of human disease. Mannosidosis. Swainsonine-induced mannosidosis.

Authors:  C R Huxtable; P R Dorling
Journal:  Am J Pathol       Date:  1982-04       Impact factor: 4.307

9.  Swainsonine, a potent mannosidase inhibitor, elevates rat liver and brain lysosomal alpha-D-mannosidase, decreases Golgi alpha-D-mannosidase II, and increases the plasma levels of several acid hydrolases.

Authors:  D R Tulsiani; O Touster
Journal:  Arch Biochem Biophys       Date:  1983-07-15       Impact factor: 4.013

10.  Fine structure of rat intrafusal muscle fibers. The equatorial region.

Authors:  W K Ovalle
Journal:  J Cell Biol       Date:  1972-02       Impact factor: 10.539

View more
  2 in total

1.  Swainsonine as a lysosomal toxin affects dopaminergic neurons.

Authors:  Qinfan Li; Yingzi Wang; Rudolf Moldzio; Weimin Lin; Wolf-Dieter Rausch
Journal:  J Neural Transm (Vienna)       Date:  2012-06-24       Impact factor: 3.575

2.  Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse.

Authors:  Ying Sun; Huimin Ran; Matt Zamzow; Kazuyuki Kitatani; Matthew R Skelton; Michael T Williams; Charles V Vorhees; David P Witte; Yusuf A Hannun; Gregory A Grabowski
Journal:  Hum Mol Genet       Date:  2009-12-16       Impact factor: 6.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.